Show simple item record

Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

dc.contributor.author Allott, EH
dc.contributor.author Howard, LE
dc.contributor.author Cooperberg, MR
dc.contributor.author Kane, CJ
dc.contributor.author Aronson, WJ
dc.contributor.author Terris, MK
dc.contributor.author Amling, CL
dc.contributor.author Freedland, SJ
dc.coverage.spatial England
dc.date.accessioned 2014-05-06T14:09:01Z
dc.date.issued 2014-11
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/24588774
dc.identifier.uri https://hdl.handle.net/10161/8617
dc.description.abstract OBJECTIVE: To investigate the effect of statin use after radical prostatectomy (RP) on biochemical recurrence (BCR) in patients with prostate cancer who never received statins before RP. PATIENTS AND METHODS: We conducted a retrospective analysis of 1146 RP patients within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Multivariable Cox proportional hazards analyses were used to examine differences in risk of BCR between post-RP statin users vs nonusers. To account for varying start dates and duration of statin use during follow-up, post-RP statin use was treated as a time-dependent variable. In a secondary analysis, models were stratified by race to examine the association of post-RP statin use with BCR among black and non-black men. RESULTS: After adjusting for clinical and pathological characteristics, post-RP statin use was significantly associated with 36% reduced risk of BCR (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.47-0.87; P = 0.004). Post-RP statin use remained associated with reduced risk of BCR after adjusting for preoperative serum cholesterol levels. In secondary analysis, after stratification by race, this protective association was significant in non-black (HR 0.49, 95% CI 0.32-0.75; P = 0.001) but not black men (HR 0.82, 95% CI 0.53-1.28; P = 0.384). CONCLUSION: In this retrospective cohort of men undergoing RP, post-RP statin use was significantly associated with reduced risk of BCR. Whether the association between post-RP statin use and BCR differs by race requires further study. Given these findings, coupled with other studies suggesting that statins may reduce risk of advanced prostate cancer, randomised controlled trials are warranted to formally test the hypothesis that statins slow prostate cancer progression.
dc.language eng
dc.relation.ispartof BJU Int
dc.relation.isversionof 10.1111/bju.12720
dc.subject biochemical recurrence
dc.subject cholesterol
dc.subject postoperative statin use
dc.subject prostate cancer
dc.subject Aged
dc.subject Databases, Factual
dc.subject Humans
dc.subject Hydroxymethylglutaryl-CoA Reductase Inhibitors
dc.subject Male
dc.subject Middle Aged
dc.subject Neoplasm Recurrence, Local
dc.subject Postoperative Period
dc.subject Proportional Hazards Models
dc.subject Prostatectomy
dc.subject Prostatic Neoplasms
dc.subject Retrospective Studies
dc.subject Risk
dc.subject United States
dc.title Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
dc.type Journal article
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/24588774
pubs.begin-page 661
pubs.end-page 666
pubs.issue 5
pubs.organisational-group Duke
pubs.organisational-group Staff
pubs.publication-status Published
pubs.volume 114
dc.identifier.eissn 1464-410X


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record